Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TAK-169 |
Synonyms | |
Therapy Description |
TAK-169 is an engineered toxin body comprising a fragment of CD38 antibody fused to Shiga-like toxin A-subunit (SLTA) that inactivates ribosomes, which potentially inhibits protein synthesis leading to killing of CD38-expressing cancer cells and tumor regression (Cancer Res 2019;79(13 Suppl):Abstract nr 2384). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAK-169 | TAK169|TAK 169 | CD38 Antibody 17 | TAK-169 is an engineered toxin body comprising a fragment of CD38 antibody fused to Shiga-like toxin A-subunit (SLTA) that inactivates ribosomes, which potentially inhibits protein synthesis leading to killing of CD38-expressing cancer cells and tumor regression (Cancer Res 2019;79(13 Suppl):Abstract nr 2384). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04017130 | Phase I | TAK-169 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Recruiting | USA | 0 |